vs
Side-by-side financial comparison of BioNTech SE (BNTX) and Globe Life (GL). Click either name above to swap in a different company.
Globe Life is the larger business by last-quarter revenue ($1.6B vs $1.5B, roughly 1.0× BioNTech SE). Globe Life runs the higher net margin — 17.3% vs -1.9%, a 19.2% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Globe Life Inc. (GL) is an American financial services holding company listed on the New York Stock Exchange which operates through its wholly owned subsidiaries providing life insurance, annuity, and supplemental health insurance products. The company is based in McKinney, Texas.
BNTX vs GL — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.6B |
| Net Profit | $-28.7M | $270.5M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | — |
| Net Margin | -1.9% | 17.3% |
| Revenue YoY | — | 5.3% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $3.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | $1.5B | $1.5B | ||
| Q2 25 | $260.8M | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | $270.5M | ||
| Q4 25 | — | $266.1M | ||
| Q3 25 | $-28.7M | $387.8M | ||
| Q2 25 | $-386.6M | $252.7M | ||
| Q1 25 | — | $254.6M | ||
| Q4 24 | — | $255.2M | ||
| Q3 24 | $198.1M | $303.0M | ||
| Q2 24 | — | $258.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 26.1% | ||
| Q2 24 | — | 23.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 21.7% | ||
| Q3 25 | -3.1% | 31.5% | ||
| Q2 25 | -192.1% | 21.2% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | 21.3% | ||
| Q3 24 | 0.8% | 26.3% | ||
| Q2 24 | — | 23.5% |
| Q1 26 | — | 17.3% | ||
| Q4 25 | — | 17.5% | ||
| Q3 25 | -1.9% | 25.6% | ||
| Q2 25 | -148.2% | 17.1% | ||
| Q1 25 | — | 17.2% | ||
| Q4 24 | — | 17.4% | ||
| Q3 24 | 15.9% | 20.8% | ||
| Q2 24 | — | 17.9% |
| Q1 26 | — | $3.39 | ||
| Q4 25 | — | $3.28 | ||
| Q3 25 | — | $4.73 | ||
| Q2 25 | — | $3.05 | ||
| Q1 25 | — | $3.01 | ||
| Q4 24 | — | $3.00 | ||
| Q3 24 | — | $3.44 | ||
| Q2 24 | — | $2.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $183.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $6.1B |
| Total Assets | — | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $183.8M | ||
| Q4 25 | — | $314.7M | ||
| Q3 25 | — | $62.8M | ||
| Q2 25 | — | $116.7M | ||
| Q1 25 | — | $134.1M | ||
| Q4 24 | — | $85.0M | ||
| Q3 24 | — | $100.5M | ||
| Q2 24 | — | $100.6M |
| Q1 26 | — | $6.1B | ||
| Q4 25 | — | $6.0B | ||
| Q3 25 | — | $5.7B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $5.3B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $5.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | $30.8B | ||
| Q3 25 | — | $30.5B | ||
| Q2 25 | — | $29.8B | ||
| Q1 25 | — | $29.7B | ||
| Q4 24 | — | $29.1B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $28.3B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BNTX
Segment breakdown not available.
GL
| Life premium | $853.2M | 55% |
| Health premium | $416.9M | 27% |
| Other | $289.5M | 19% |
